patient. Initial review three to six monthly. If there is no benefit after this treatment, IVIg months. therapy should be abandoned. For stable patients on maintenance treatment review by a neurologist is required at least Review by a Neurologist is required within four annually. months of treatment and annually thereafter. Effectiveness Clinical documentation of effectiveness is necessary for continuation of IVIg therapy. Clinical documentation of effectiveness is necessary for continuation of IVIg therapy. Effectiveness can be demonstrated by objective On review of an initial authorisation period findings of either: Re-authorisation may only be approved where an Improvement in functional scores activities of daily improvement in impairment as demonstrated by: living (ADL) or quantitative muscle scores or Clinically significant improvement in Medical Research Council (MRC) muscle muscle weakness as measured by an assessment; increase in the MRC Sum (12) Score A link to MRC Scoring system will be compared to the qualifying score. available within the system: OR OR Kleyweg RP, van der Meche FGA, Stabilisation of disease as defined by stable A clinically significant improvement in the Schmitz PIM. Muscle Nerve functional scores (ADLs) or quantitative muscle severity of autonomic symptoms 1991;14:1103-1109 scores or MRC muscle assessment after compared to the severity of symptoms at previous evidence of deterioration in one of qualifying. these scores. On review of a continuing authorisation period
patient. Initial review three to six monthly. For stable patients on maintenance treatment review by a neurologist is required at least annually. Effectiveness Clinical documentation of effectiveness is necessary for continuation of IVIg therapy. Effectiveness can be demonstrated by objective findings of either: Improvement in functional scores activities of daily living (ADL) or quantitative muscle scores or Medical Research Council (MRC) muscle assessment; OR Stabilisation of disease as defined by stable functional scores (ADLs) or quantitative muscle scores or MRC muscle assessment after previous evidence of deterioration in one of these scores. If there is no benefit after this treatment, IVIg therapy should be abandoned. Review by a Neurologist is required within four months of treatment and annually thereafter. Clinical documentation of effectiveness is necessary for continuation of IVIg therapy. On review of an initial authorisation period Re-authorisation may only be approved where an improvement in impairment as demonstrated by: Clinically significant improvement in muscle weakness as measured by an increase in the MRC Sum (12) Score compared to the qualifying score. OR A clinically significant improvement in the severity of autonomic symptoms compared to the severity of symptoms at qualifying. On review of a continuing authorisation period months. A link to MRC Scoring system will be available within the system: Kleyweg RP, van der Meche FGA, Schmitz PIM. Muscle Nerve 1991;14:1103-1109